医学
冠状动脉疾病
重症监护医学
临床试验
心脏病学
冠状动脉
内科学
动脉
作者
Islam Y. Elgendy,Lina Ya’qoub,Kuan-Han Chen,Carl J. Pepine
出处
期刊:Drugs
[Adis, Springer Healthcare]
日期:2022-01-29
卷期号:82 (3): 241-250
被引量:9
标识
DOI:10.1007/s40265-021-01667-y
摘要
There has been increasing interest in open artery syndrome, also known as ischemia with non-obstructive coronary arteries (INOCA). INOCA has been increasingly recognized as a heterogeneous clinical entity. Diagnostic evaluation of this heterogeneous entity, including invasive assessment, remains key to diagnose this clinical condition and provide the appropriate treatment. Importantly, medical stratification based on the type of INOCA has shown benefit in improving the symptoms in these patients, as illustrated in the CorMicA trial. The Women's IschemiA Trial to Reduce Events in Non-ObstRuctIve CORonary Artery Disease (WARRIOR) is another promising landmark trial that is currently enrolling patients and will address some of the unanswered questions for management of women with INOCA. In this review, we discuss the pathophysiology, management options, knowledge gaps, and future directions while highlighting the rationale and design of the ongoing WARRIOR trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI